AstraZeneca enters strategic equity investment and clinical collaboration with Summit Therapeutics to advance leading ADC combination strategy in cancer

AstraZeneca has entered into an agreement to invest $2 billion in newly issued equity in Summit Therapeutics Inc. to accelerate the development of ivonescimab, a first─in─class bispecific antibody targeting PD─1 and